Rosonabant

Last updated
Rosonabant
Rosonabant.svg
Clinical data
ATC code
  • None
Identifiers
  • (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-piperidinyl)-4,5-dihydro-1H-pyrazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C21H21Cl3N4O
Molar mass 451.78 g·mol−1
3D model (JSmol)
  • O=C(NN1CCCCC1)\C4=N\N(c2ccc(Cl)cc2Cl)C(c3ccc(Cl)cc3)C4
  • InChI=1S/C21H21Cl3N4O/c22-15-6-4-14(5-7-15)20-13-18(21(29)26-27-10-2-1-3-11-27)25-28(20)19-9-8-16(23)12-17(19)24/h4-9,12,20H,1-3,10-11,13H2,(H,26,29)
  • Key:WMMMJGKFKKBRQR-UHFFFAOYSA-N

Rosonabant (INN; E-6776) is a drug acting as a CB1 receptor antagonist/inverse agonist that was under investigation by Esteve as an appetite suppressant for the treatment of obesity. [1] [2] Development of the drug for clinical use was apparently halted shortly after the related CB1 antagonist rimonabant was discovered to have serious adverse effects such as anxiety, clinical depression, and suicidal ideation. [3] [4] [5]

See also

References

  1. ↑ Janero DR, Makriyannis A (March 2009). "Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis". Expert Opinion on Emerging Drugs. 14 (1): 43–65. doi:10.1517/14728210902736568. PMID   19249987. S2CID   74250986.
  2. ↑ Vickers SP, Cheetham SC (2007). "Preclinical Developments in Antiobesity Drugs". In Kirkham TC, Cooper SJ (eds.). Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. p. 325. ISBN   978-0-12-370633-1 . Retrieved 12 May 2012.
  3. ↑ Heal DJ, Gosden J, Smith SL (December 2009). "Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders". British Journal of Clinical Pharmacology. 68 (6): 861–874. doi:10.1111/j.1365-2125.2009.03549.x. PMC   2810797 . PMID   20002080.
  4. ↑ Lee HK, Choi EB, Pak CS (2009). "The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current Topics in Medicinal Chemistry. 9 (6): 482–503. doi:10.2174/156802609788897844. PMID   19689362. Archived from the original on 2013-05-22.
  5. ↑ Moreira FA, Crippa JA (June 2009). "The psychiatric side-effects of rimonabant". Revista Brasileira de Psiquiatria. 31 (2): 145–153. doi: 10.1590/S1516-44462009000200012 . PMID   19578688.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.